On 27 October 2011, orphan designation (EU/3/11/926) was granted by the European Commission to Adienne S.r.l, Italy, for recombinant human minibody against complement component C5 for the treatment of primary membranoproliferative glomerulonephritis.
In January 2014, ADIENNE S.r.l. changed name to ADIENNE S.r.l.S.U.
For a list of the administrative updates to this public summary of opinion please refer to the PDF document below.
Please note that this product was withdrawn from the Community Register of designated Orphan Medicinal Products in April 2019 on request of the Sponsor.
EU/03/11/926: Public summary of opinion on orphan designation: Recombinant human minibody against complement component C5 for the treatment of primary membranoproliferative glomerulonephritis (PDF/147.4 KB)
First published: 23/11/2011
Last updated: 22/01/2014
Recombinant human minibody against complement component C5
|Disease / condition||
Treatment of primary membranoproliferative glomerulonephritis
|Date of decision||
|Orphan decision number||
Review of designation
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
- European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
- Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;